Covered recipient · General Payments record
SREEDHAR MANDAYAM
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$146,326.93
210 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $89,431.00 | 30 |
| Honoraria | $27,437.50 | 8 |
| Travel and Lodging | $18,899.89 | 67 |
| Food and Beverage | $5,613.88 | 98 |
| Consulting Fee | $4,875.00 | 3 |
| Education | $69.66 | 4 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Mallinckrodt Enterprises LLC | $84,928.18 | 95 |
| Horizon Therapeutics plc | $33,174.79 | 37 |
| AMAG Pharmaceuticals, Inc. | $12,669.86 | 18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $7,526.22 | 15 |
| Janssen Pharmaceuticals, Inc | $4,665.75 | 6 |
| Relypsa, Inc. | $1,547.12 | 3 |
| AstraZeneca Pharmaceuticals LP | $703.45 | 10 |
| Amgen Inc. | $341.34 | 5 |
| Alexion Pharmaceuticals, Inc. | $197.33 | 4 |
| Otsuka America Pharmaceutical, Inc. | $111.37 | 5 |
| Retrophin, Inc. | $80.81 | 1 |
| OPKO Pharmaceuticals, LLC | $75.10 | 2 |
| NxStage Medical, Inc. | $63.06 | 2 |
| AKEBIA THERAPEUTICS INC | $60.33 | 2 |
| Kaneka Pharma America LLC | $56.87 | 1 |
| AngioDynamics, Inc. | $48.81 | 1 |
| Allergan Inc. | $27.09 | 1 |
| BTG International, Inc. | $25.44 | 1 |
| Fresenius USA Marketing, Inc. | $24.01 | 1 |
Page 4 of 5; records 151–200 of 210 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SREEDHAR MANDAYAM
NPI 1225051048 · CMS profile ID 55677
Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 5; records 151–200 of 210 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1225051048?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SREEDHAR MANDAYAM, NPI 1225051048, CMS profile ID 55677. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 210 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1225051048?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). SREEDHAR MANDAYAM, NPI 1225051048, CMS profile ID 55677. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 210 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1225051048?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- SREEDHAR MANDAYAM, NPI 1225051048, CMS profile ID 55677, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 210 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1225051048?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
210 matching records · $146,326.93 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 210.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Enterprises LLC | $4,700.00 | 05/29/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760245 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $24.08 | 05/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 696054997 | CMS |
| Mallinckrodt Enterprises LLC | $196.47 | 05/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760243 | CMS |
| Amgen Inc. | $8.75 | 05/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663057587 | CMS |
| Mallinckrodt Enterprises LLC | $125.00 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760235 | CMS |
| Mallinckrodt Enterprises LLC | $15.63 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760237 | CMS |
| Mallinckrodt Enterprises LLC | $737.10 | 05/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760239 | CMS |
| Mallinckrodt Enterprises LLC | $890.00 | 05/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760241 | CMS |
| Amgen Inc. | $104.29 | 05/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663057591 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $16.60 | 05/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709108245 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $24.00 | 05/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709108247 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $2.40 | 05/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709108249 | CMS |
| Alexion Pharmaceuticals, Inc. | $125.00 | 05/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695582471 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,948.00 | 05/14/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709108243 | CMS |
| AKEBIA THERAPEUTICS INC | $16.27 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706557423 | CMS |
| Alexion Pharmaceuticals, Inc. | $14.69 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695582277 | CMS |
| Horizon Therapeutics plc | $12.61 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691437589 | CMS |
| Mallinckrodt Enterprises LLC | $113.46 | 05/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760229 | CMS |
| Mallinckrodt Enterprises LLC | $3,000.00 | 05/08/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760231 | CMS |
| Mallinckrodt Enterprises LLC | $38.48 | 05/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760233 | CMS |
| OPKO Pharmaceuticals, LLC | $12.16 | 05/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 707773707 | CMS |
| AstraZeneca Pharmaceuticals LP | $50.34 | 05/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685329181 | CMS |
| AstraZeneca Pharmaceuticals LP | $116.15 | 05/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685763993 | CMS |
| Horizon Therapeutics plc | $116.50 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691437585 | CMS |
| Mallinckrodt Enterprises LLC | $2,700.00 | 04/15/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760227 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $202.74 | 04/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709108241 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $265.96 | 04/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709108237 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $76.40 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709108239 | CMS |
| Otsuka America Pharmaceutical, Inc. | $22.70 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687430213 | CMS |
| Mallinckrodt Enterprises LLC | $39.62 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760225 | CMS |
| Mallinckrodt Enterprises LLC | $163.20 | 03/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741409617 | CMS |
| Mallinckrodt Enterprises LLC | $45.65 | 03/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741409621 | CMS |
| Mallinckrodt Enterprises LLC | $9.60 | 03/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741409627 | CMS |
| Mallinckrodt Enterprises LLC | $51.91 | 03/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741409631 | CMS |
| Mallinckrodt Enterprises LLC | $9.60 | 03/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741409635 | CMS |
| Mallinckrodt Enterprises LLC | $27.40 | 03/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741409641 | CMS |
| Mallinckrodt Enterprises LLC | $595.96 | 03/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741409599 | CMS |
| Mallinckrodt Enterprises LLC | $158.46 | 03/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741409605 | CMS |
| Mallinckrodt Enterprises LLC | $113.75 | 03/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741409611 | CMS |
| AMAG Pharmaceuticals, Inc. | $800.00 | 03/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698527957 | CMS |
| Mallinckrodt Enterprises LLC | $4,400.00 | 03/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760223 | CMS |
| Mallinckrodt Enterprises LLC | $113.12 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704760221 | CMS |
| NxStage Medical, Inc. | $27.89 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705346087 | CMS |
| Otsuka America Pharmaceutical, Inc. | $2.74 | 02/23/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687430211 | CMS |
| Horizon Therapeutics plc | $511.60 | 02/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691437567 | CMS |
| Horizon Therapeutics plc | $394.50 | 02/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691437571 | CMS |
| Horizon Therapeutics plc | $280.13 | 02/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691437575 | CMS |
| Horizon Therapeutics plc | $5,850.00 | 02/20/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691437577 | CMS |
| Horizon Therapeutics plc | $63.50 | 02/20/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691437581 | CMS |
| Horizon Therapeutics plc | $107.83 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691437563 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,127,970.53 | 107 |
| PY2024 | Principal investigator | $895,420.04 | 111 |
| PY2023 | Recipient | $1,102.18 | 5 |
| PY2023 | Principal investigator | $1,491,067.06 | 536 |
| PY2022 | Principal investigator | $892,861.29 | 510 |
| PY2021 | Principal investigator | $376,074.08 | 272 |
| PY2020 | Recipient | $940.00 | 1 |
| PY2020 | Principal investigator | $318,747.22 | 133 |
| PY2019 | Principal investigator | $116,318.40 | 15 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
107 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,300.00 | 12/15/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226114022 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $5,276.00 | 11/25/2025 | Non-covered Recipient Entity Prolato Clinical Research Center | A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy | No dispute reported | 06/30/2026 | 1190341949 |
| Principal investigator 1 | AstraZeneca UK Limited | $19,090.00 | 11/19/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) | No dispute reported | 06/30/2026 | 1185546055 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,700.00 | 11/17/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226114011 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13.46 | 11/15/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients | No dispute reported | 06/30/2026 | 1190310863 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15.74 | 11/15/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) | No dispute reported | 06/30/2026 | 1190310865 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,172.80 | 11/12/2025 | Non-covered Recipient Entity PROVECTA RESEARCH NETWORK LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223288289 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,245.00 | 11/10/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226114001 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $32,855.90 | 10/29/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER KIRBY DR | A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy | No dispute reported | 06/30/2026 | 1214124500 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $8,732.00 | 10/28/2025 | Non-covered Recipient Entity Prolato Clinical Research Center | A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy | No dispute reported | 06/30/2026 | 1190341946 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,845.00 | 10/20/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113992 |
| Principal investigator 1 | AstraZeneca UK Limited | $54,332.16 | 10/10/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) | No dispute reported | 06/30/2026 | 1185546045 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $423,000.67 | 10/08/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy Receiving Iptacopan on Top of Supportive Care | No dispute reported | 06/30/2026 | 1190309966 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19.74 | 10/08/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190310867 |
| Principal investigator 1 | Calliditas Therapeutics US Inc. | $1,511.11 | 10/07/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Nef-403 | No dispute reported | 06/30/2026 | 1235023486 |
| Principal investigator 1 | Calliditas Therapeutics US Inc. | $1,250.16 | 10/07/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Nef-403 | No dispute reported | 06/30/2026 | 1235023504 |
| Principal investigator 1 | GENZYME CORPORATION | $4,817.00 | 09/29/2025 | Non-covered Recipient Entity Prolato Research Llc | ACT - POC clinical study - CD40L mAb - frexalimab | No dispute reported | 06/30/2026 | 1226113981 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,200.00 | 09/29/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113987 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,062.50 | 09/10/2025 | Non-covered Recipient Entity PROVECTA RESEARCH NETWORK LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223285285 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,995.00 | 09/10/2025 | Non-covered Recipient Entity PROVECTA RESEARCH NETWORK LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223285287 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,822.50 | 09/10/2025 | Non-covered Recipient Entity PROVECTA RESEARCH NETWORK LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223285289 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $18,900.00 | 09/02/2025 | Non-covered Recipient Entity PROVECTA RESEARCH NETWORK LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223284741 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $39,400.00 | 08/25/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113972 |
| Principal investigator 1 | Novo Nordisk AS | $450.00 | 08/22/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | NN9535-4662 | No dispute reported | 06/30/2026 | 1213709529 |
| Principal investigator 1 | Novo Nordisk AS | $593.74 | 08/22/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | NN9535-4662 | No dispute reported | 06/30/2026 | 1213827883 |
| Principal investigator 1 | Calliditas Therapeutics US Inc. | $4,723.44 | 08/12/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Nef-403 | No dispute reported | 06/30/2026 | 1235023466 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $20,800.00 | 08/04/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113944 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,375.00 | 08/04/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113949 |
| Principal investigator 1 | Amgen Inc. | $4,050.00 | 08/01/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC PROLATO CLINICAL RESEARCH CENTER | A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases | No dispute reported | 06/30/2026 | 1246646864 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $675.00 | 07/18/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639076 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $202.50 | 07/18/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639079 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $623.10 | 07/18/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639083 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,515.00 | 07/14/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113928 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,191.11 | 07/09/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) | No dispute reported | 06/30/2026 | 1190310142 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,512.00 | 07/02/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113918 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $26,370.00 | 07/02/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113936 |
| Principal investigator 1 | Novo Nordisk AS | $20,688.72 | 06/25/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | NN9535-4662 | No dispute reported | 06/30/2026 | 1213734214 |
| Principal investigator 1 | Novo Nordisk AS | $4,025.00 | 06/25/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | NN9535-4662 | No dispute reported | 06/30/2026 | 1213803996 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $210,958.90 | 06/23/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy Receiving Iptacopan on Top of Supportive Care | No dispute reported | 06/30/2026 | 1190310138 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,000.80 | 06/23/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244185953 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $467.50 | 06/18/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639059 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,025.00 | 06/18/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639064 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $623.10 | 06/18/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639068 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $59.40 | 06/18/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639072 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $44.00 | 06/16/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244186887 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $313.00 | 06/16/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244186895 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $300.00 | 06/16/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244186902 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $39.00 | 06/16/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244186906 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $125.00 | 06/16/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244186910 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,950.00 | 06/12/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) | No dispute reported | 06/30/2026 | 1190310837 |
| Principal investigator 1 | Calliditas Therapeutics US Inc. | $15,000.03 | 06/04/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Nef-403 | No dispute reported | 06/30/2026 | 1235023442 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $7,037.90 | 06/03/2025 | Non-covered Recipient Entity Prolato Clinical Research Center | A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy | No dispute reported | 06/30/2026 | 1190339034 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,000.00 | 06/03/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) | No dispute reported | 06/30/2026 | 1190310831 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,782.12 | 05/27/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113869 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $30,542.00 | 05/27/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113874 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,468.24 | 05/19/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113880 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $126.00 | 05/16/2025 | Non-covered Recipient Entity Prolato Research LLC | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244186891 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $500.00 | 05/16/2025 | Non-covered Recipient Entity Prolato Research LLC | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244186898 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 04/23/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | NN9535-4662 | No dispute reported | 06/30/2026 | 1213752638 |
| Principal investigator 1 | Novo Nordisk AS | $1,875.00 | 04/23/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | NN9535-4662 | No dispute reported | 06/30/2026 | 1213812549 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,597.15 | 04/18/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases | No dispute reported | 06/30/2026 | 1190310130 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,346.60 | 04/08/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190310150 |
| Principal investigator 1 | Novo Nordisk AS | $2,630.00 | 03/31/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | NN9535-4662 | No dispute reported | 06/30/2026 | 1213710042 |
| Principal investigator 1 | Novo Nordisk AS | $675.00 | 03/31/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | NN9535-4662 | No dispute reported | 06/30/2026 | 1213743224 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,083.15 | 03/26/2025 | Non-covered Recipient Entity MD ANDERSON CANCER CENTER UNIVERSITY OF TEXAS | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study) | No dispute reported | 06/30/2026 | 1190306949 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,616.00 | 03/17/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113832 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $25,020.00 | 03/11/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy Receiving Iptacopan on Top of Supportive Care | No dispute reported | 06/30/2026 | 1190309982 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $25,770.70 | 03/06/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | No dispute reported | 06/30/2026 | 1185546047 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,154.00 | 03/03/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244183750 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $740.10 | 03/03/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244183754 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,154.00 | 03/03/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244183758 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,154.00 | 03/03/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244183762 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $32,490.50 | 02/24/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113819 |
| Principal investigator 1 | Amgen Inc. | $4,826.25 | 02/21/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Effect of Pegloticase on reduction of Uric Acid in patients with Tumor Lysis Syndrome: A Pilot Pragmatic Randomized Clinical Trial | No dispute reported | 06/30/2026 | 1246638184 |
| Principal investigator 1 | BeiGene USA, Inc. | $5,960.00 | 02/11/2025 | Non-covered Recipient Entity Prolato Research LLC | A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy | No dispute reported | 06/30/2026 | 1190320504 |
| Principal investigator 1 | GENZYME CORPORATION | $22,415.00 | 02/04/2025 | Non-covered Recipient Entity Prolato Research Llc | ACT - POC clinical study - CD40L mAb - frexalimab | No dispute reported | 06/30/2026 | 1226113837 |
| Principal investigator 1 | AstraZeneca UK Limited | $35,544.90 | 02/03/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185546053 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $33,422.50 | 01/28/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190310835 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $147,615.82 | 01/27/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER KIRBY DR | A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease | No dispute reported | 06/30/2026 | 1214125070 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $9,713.50 | 01/23/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | No dispute reported | 06/30/2026 | 1185546049 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,653.50 | 01/22/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases | No dispute reported | 06/30/2026 | 1190310132 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $30,003.30 | 01/21/2025 | Non-covered Recipient Entity Prolato Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113810 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $67.30 | 01/15/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients | No dispute reported | 06/30/2026 | 1190310140 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $43.50 | 01/15/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) | No dispute reported | 06/30/2026 | 1190310152 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $59.40 | 01/08/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639037 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,295.00 | 01/08/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639042 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $130.00 | 01/08/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639046 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $405.00 | 01/08/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639050 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,511.00 | 01/08/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211639055 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,500.00 | 01/07/2025 | Non-covered Recipient Entity PROLATO RESEARCH LLC | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients | No dispute reported | 06/30/2026 | 1190309984 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $189.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244183618 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $171.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244183621 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $600.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244183624 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $83.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244183628 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $700.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244183632 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $200.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244183636 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $100.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244183640 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $150.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244183644 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $300.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244183648 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $125.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244183652 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $88.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244186782 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $63.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244186786 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $313.00 | 01/07/2025 | Non-covered Recipient Entity Prolato Research LLC | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244186790 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $201,932.15 | 01/06/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER KIRBY DR | An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3) | No dispute reported | 06/30/2026 | 1214124198 |
| Principal investigator 1 | AstraZeneca UK Limited | $25,315.00 | 01/03/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185546051 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $190,210.82 | 01/02/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER KIRBY DR | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) | No dispute reported | 06/30/2026 | 1214124786 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $170,345.05 | 01/01/2025 | Non-covered Recipient Entity PROLATO CLINICAL RESEARCH CENTER IBN SINA COMMUNITY N. SHEPHERD MEDICAL DENTAL | A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease | No dispute reported | 06/30/2026 | 1214123336 |